News Conference News VIVA 2024 DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years L.A. McKeown November 11, 2024
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VIVA 2020 DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD L.A. McKeown November 09, 2020
News Conference News VIVA 2019 Future Pulmonary Embolism Interventions: Wild West or Working Together? L.A. McKeown November 14, 2019
News Conference News VIVA 2019 Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel L.A. McKeown November 08, 2019
News Conference News VIVA 2019 IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB L.A. McKeown November 05, 2019
News Conference News VIVA 2018 IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions L.A. McKeown November 06, 2018
News Conference News VIVA 2017 Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD L.A. McKeown September 18, 2017
News Conference News VIVA 2017 DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease L.A. McKeown September 13, 2017
News Conference News VIVA 2016 Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear L.A. McKeown September 21, 2016
News Conference News VIVA 2016 Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent L.A. McKeown September 20, 2016